招待講演6

[SK6-1] Diagnostic 131-I scintigraphy with SPECT/CT for the management of thyroid cancer

^○Anca M. Avram (Department of Radiology University of Michigan Medical Center, USA)

Anca M. Avram is Associate Professor of Radiology at the University of Michigan, in Ann Arbor, USA where she currently serves as Director of the Nuclear Medicine Therapy Program. After she received her medical degree, Dr. Avram pursued initial post-graduate training in Internal Medicine, and then she completed two fellowships at the University of Michigan: one in Endocrinology, Metabolism and Diabetes, and the other in Nuclear Medicine. In 2005, Dr. Avram joined the faculty of the University of Michigan specializing in nuclear medicine and radionuclide therapies, and she has developed a strong nuclear medicine therapy program at clinical research, patient care, and post-graduate medical education. During this time she has been a contributing author on 48 peer reviewed scientific manuscripts, 48 abstract presentations at national meetings and 8 book chapters. Dr. Avram's clinical interests include radioactive iodine treatment for hyperthyroidism, thyroid cancer and radioimmunotherapy for lymphoma. Dr. Avram's research interests focus on the role of diagnostic radioiodine imaging for guiding 131-I treatment for thyroid cancer, and clinical dosimetry protocols for metastatic thyroid cancer. Building on a solid clinical foundation, Dr. Avram continues a vibrant clinical research program at the University of Michigan. NIH-funded research in radio-immunotherapy (NIH grant: SPECT/CT Image-Based Dosimetry in radionuclide therapy and NIH grant: Imaging Based Dosimetry for Individualized Internal Emitter Therapy) has been conducted in the Nuclear Medicine Therapy Clinic for many years, along with research in thyroid cancer imaging-based staging, patient risk stratification prior to radioiodine therapy and tumor dosimetry.
Dr. Avram is certified by the American Board of Internal Medicine, the American Board of Endocrinology & Metabolism, and the American Board of Nuclear Medicine. She is a member of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Endocrine Society. Due to her nationally recognized expertise in the field of thyroid cancer, Dr. Avram has been an invited speaker for numerous SNMMI meetings, ATA meetings, for the National Graves' Disease Foundation Conference, the Thyroid Cancer Survivors Association, and the American Association of Clinical Endocrinologists (AACE).